Pulmonary fibrosis (PF) is a chronic, progressive, and lethal disease with little response to available therapies. One of the major mechanisms of PF is the repeated injury and inadequate regeneration of the alveolar epithelium. In this study, we induced human umbilical cord mesenchymal stem cells (hUC-MSCs) to differentiate into type 2 alveolar epithelial cells (AEC2s), and we provided evidence that intratracheal transplantation of hUC-MSC-derived AEC2s (MSC-AEC2s) could improve mortality and alleviate fibrosis in bleomycin-induced PF mice. Transplantation of MSC-AEC2s could increase the AEC2 cell count in these mice, and the results of the cell tracing experiment exhibited that the increased AEC2s originated from the self-renewal of mouse alveolar epithelium. The AEC2 survival was controlled by the apoptosis of AEC2s via the expression of β-catenin in PF mice. In in vitro experiments, MSC-AEC2s could alleviate the apoptosis of MLE-12 cells induced by transforming growth factor beta (TGF-β1), which could be eliminated by using PRI-724, a β-catenin inhibitor, suggesting β-catenin signaling involved in the protection against apoptosis provided by MSC-AEC2s. Our study demonstrated that MSC-AEC2s could protect PF mice through regulating apoptosis mediated by β-catenin, which provided a viable strategy for the treatment of PF.
Get full access to this article
View all access options for this article.
References
1.
LedererDJ and MartinezFJ. (2018). Idiopathic pulmonary fibrosis. N Engl J Med, 378:1811–1823.
RicheldiL, CollardHR and JonesMG. (2017). Idiopathic pulmonary fibrosis. Lancet, 389:1941–1952.
4.
ZhaoX, KwanJYY, YipK, LiuPP and LiuFF. (2020). Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov, 19:57–75.
5.
GeorgePM, PattersonCM, ReedAK and ThillaiM. (2019). Lung transplantation for idiopathic pulmonary fbrosis. Lancet Respir Med, 7:271–282.
6.
Karimi-ShahBA and ChowdhuryBA. (2015). Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib. N Engl J Med, 372:1189–1191.
7.
MoraAL, RojasM, PardoA and SelmanM. (2017). Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat Rev Drug Discov, 16:810.
8.
MazzeiME, RicheldiL and CollardHR. (2015). Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis, 9:121–129.
9.
CottinV and MaherT. (2015). Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev, 24:58–64.
10.
CaoZ, LisR, GinsbergM, ChavezD, ShidoK, RabbanySY, FongGH, SakmarTP, RafiiS and DingBS. (2016). Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis. Nat Med, 22:154–162.
11.
DesaiTJ, BrownfieldDG and KrasnowMA. (2014). Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature, 507:190–194.
12.
SaidSI, KleinRM, NorrellLW and MaddoxYT. (1966). Metabolism of alveolar cells: histochemical evidence and relation to pulmonary surfactant. Science, 152:657–659.
13.
ChoiJ, ParkJE, TsagkogeorgaG, YanagitaM, KooBK, HanN and LeeJH. (2020). Inflammatory signals induce AT2 cell-derived damage-associated transient progenitors that mediate alveolar regeneration. Cell Stem Cell, 27:366–382.e7.
14.
SelmanM and PardoA. (2006). Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc, 3:364–372.
15.
SissonTH, MendezM, ChoiK, SubbotinaN, CoureyA, CunninghamA, DaveA, EngelhardtJF, LiuX, et al. (2010). Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med, 181:254–263.
16.
KingTEJr, PardoA and SelmanM. (2011). Idiopathic pulmonary fibrosis. Lancet, 378:1949–1961.
17.
KobayashiY, TataA, KonkimallaA, KatsuraH, LeeRF, OuJ, BanovichNE, KropskiJA and TataPR. (2020). Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis. Nat Cell Biol, 22:934–946.
18.
SelmanM and PardoA. (2020). The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis. Cell Signal, 66:109482.
19.
Serrano-MollarA, NacherM, Gay-JordiG, ClosaD, XaubetA and BulbenaO. (2007). Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med, 176:1261–1268.
20.
Guillamat-PratsR, Gay-JordiG, XaubetA, PeinadoVI and Serrano-MollarA. (2014). Alveolar type II cell transplantation restores pulmonary surfactant protein levels in lung fibrosis. J Heart Lung Transplant, 33:758–765.
21.
Serrano-MollarA, Gay-JordiG, Guillamat-PratsR, ClosaD, Hernandez-GonzalezF, MarinP, BurgosF, MartorellJ, SánchezM, et al. (2016). Safety and tolerability of alveolar type II cell transplantation in idiopathic pulmonary fibrosis. Chest, 150:533–543.
22.
KassemDH and KamalMM. (2020). Wharton's Jelly MSCs: potential weapon to sharpen for our battle against DM. Trends Endocrinol Metab, 31:271–273.
23.
DorronsoroA and RobbinsPD. (2013). Regenerating the injured kidney with human umbilical cord mesenchymal stem cell-derived exosomes. Stem Cell Res Ther, 4:39.
24.
AnSY, JangYJ, LimHJ, HanJ, LeeJ, LeeG, ParkJY, ParkSY, KimJH, et al. (2017). Milk fat globule-EGF factor 8, secreted by mesenchymal stem cells, protects against liver fibrosis in mice. Gastroenterology, 152:1174–1186.
25.
LiuFB, LinQ and LiuZW. (2016). A study on the role of apoptotic human umbilical cord mesenchymal stem cells in bleomycin-induced acute lung injury in rat models. Eur Rev Med Pharmacol Sci, 20:969–982.
26.
YouJ, ZhouO, LiuJ, ZouW, ZhangL, TianD, DaiJ, LuoZ, LiuE, FuZ and ZouL. (2020). Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles alleviate lung injury in rat model of bronchopulmonary dysplasia by affecting cell survival and angiogenesis. Stem Cells Dev 2020, 29:1520–1532.
27.
DingDC, ShyuWC, ChiangMF, LinSZ, ChangYC, WangHJ, SuCY and LiH. (2007). Enhancement of neuroplasticity through up-regulation of beta1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis, 27:339–353.
28.
YangH, XieZ, WeiL, YangH, YangS, ZhuZ, WangP, ZhaoC and BiJ. (2013). Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an AβPP/PS1 transgenic mouse model. Stem Cell Res Ther, 4:76.
29.
CampardD, LysyPA, NajimiM and SokalEM. (2008). Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology, 134:833–848.
30.
TsaiPJ, WangHS, ShyrYM, WengZC, TaiLC, ShyuJF and ChenTH. (2012). Transplantation of insulin producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic rats. J Biomed Sci, 19:47.
31.
QiaoY, XuZ, YuY, HouS, GengJ, XiaoT, LiangY, DongQ, MeiY, et al. (2020). Single cell derived spheres of umbilical cord mesenchymal stem cells enhance cell stemness properties, survival ability and therapeutic potential on liver failure. Biomaterials, 227:119573.
32.
TodeschiMR, El BacklyR, CapelliC, DagaA, PatroneE, IntronaM, CanceddaR and MastrogiacomoM. (2015). Transplanted umbilical cord mesenchymal stem cells modify the in vivo microenvironment enhancing angiogenesis and leading to bone regeneration. Stem Cells Dev, 24:1570–1581.
33.
LiuJ, PengD, GouH, WuX, SiD, NiuC, TianD, LiuE, ZouL and FuZ. (2018). Induction of human umbilical cord mesenchymal stem cells into type II alveolar epithelial cells in vitro. Chin J Cell Biol, 40:365–372.
34.
MessierEM, MasonRJ and KosmiderB. (2012). Efficient and rapid isolation and purification of mouse alveolar type II epithelial cells. Exp Lung Res, 38:363–373.
35.
HübnerRH, GitterW, El MokhtariNE, MathiakM, BothM, BolteH, Freitag-WolfS and BewigB. (2008). Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques, 44:507–511.
36.
PengD, SiD, ZhangR, LiuJ, GouH, XiaY, TianD, DaiJ, YangK, et al. (2017). Deletion of SMARCA4 impairs alveolar epithelial type II cells proliferation and aggravates pulmonary fibrosis in mice. Genes Dis, 4:204–214.
37.
BarkauskasCE, CronceMJ, RackleyCR, BowieEJ, KeeneDR, StrippBR, RandellSH, NoblePW and HoganBL. (2013). Type 2 alveolar cells are stem cells in adult lung. J Clin Invest, 123:3025–3036.
38.
NekantiU, RaoVB, BahirvaniAG, JanM, ToteyS and TaM. (2010). Long-term expansion and pluripotent marker array analysis of Wharton's jelly-derived mesenchymal stem cells. Stem Cells Dev, 19:117–130.
39.
VermeulenK, BernemanZN and Van BockstaeleDR. (2003). Cell cycle and apoptosis. Cell Prolif, 36:165–175.
40.
NabhanAN, BrownfieldDG, HarburyPB, KrasnowMA and DesaiTJ. (2018). Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science, 359:1118–1123.
41.
TanjoreH, DegryseAL, CrossnoPF, XuXC, Mc ConahaME, JonesBR, PolosukhinVV, BryantAJ, ChengDS, et al. (2013). b-Catenin in the alveolar epithelium protects from lung fibrosis after intratracheal bleomycin. Am J Respir Crit Care Med, 187:630–639.
42.
GhadiriM, YoungPM and TrainiD. (2016). Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. Expert Opin Biol Ther, 16:375–387.
43.
GhaediM, MendezJJ, BovePF, SivarapatnaA, RaredonMS and NiklasonLE. (2014). Alveolar epithelial differentiation of human induced pluripotent stem cells in a rotating bioreactor. Biomaterials, 35:699–710.
44.
HuangSX, IslamMN, O'NeillJ, HuZ, YangYG, ChenYW, MumauM, GreenMD, Vunjak-NovakovicG, BhattacharyaJ and SnoeckHW. (2014). Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. Nat Biotechnol, 32:84–91.
45.
WangD, HavilandDL, BurnsAR, ZsigmondE and WetselRA. (2007). A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A, 104:4449–4454.
46.
LevickSE. (2004). Ethics of embryonic stem cells. N Engl J Med, 351:1687–1690.
47.
IidaT, IwanamiA, SanosakaT, KohyamaJ, MiyoshiH, NagoshiN, KashiwagiR, ToyamaY, MatsumotoM, NakamuraM and OkanoH. (2017). Whole-genome DNA methylation analyses revealed epigenetic instability in tumorigenic human iPS cell-derived neural stem/progenitor cells. Stem Cells, 35:1316–1327.
48.
WeaverTE and WhitsettJA. (1991). Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem J, 273:249–264.
49.
XieT, LiangJ, GengY, LiuN, KurkciyanA, KulurV, LengD, DengN, LiuZ, et al. (2017). MicroRNA-29c prevents pulmonary fibrosis by regulating epithelial cell renewal and apoptosis. Am J Respir Cell Mol Biol, 57:721–732.
50.
LehmannM, KorfeiM, MutzeK, KleeS, Skronska-WasekW, AlsafadiHN, OtaC, CostaR, SchillerHB, et al. (2017). Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo. Eur Respir J, 50:1602367.
51.
KorfeiM, RuppertC, MahavadiP, HennekeI, MarkartP, KochM, LangG, FinkL, BohleRM, et al. (2008). Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 178:838–846.
52.
CarneiroPJ, ClevelarioAL, PadilhaGA, SilvaJD, KitokoJZ, OlsenPC, CapelozziVL, RoccoPR and CruzFF. (2017). Bosutinib therapy ameliorates lung inflammation and fibrosis in experimental silicosis. Front Physiol, 8:159.
53.
CleversH and NusseR. (2012). Wnt/β-catenin signaling and disease. Cell, 149:1192–1205.
54.
NelsonWJ and NusseR. (2004). Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 303:1483–1487.
55.
BienzM. (2005). Beta-catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol, 15:R64–R67.
56.
MoonRT, KohnAD, De FerrariGV and KaykasA. (2004). WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet, 5:691–701.
57.
HeX. (2003). A Wnt-Wnt situation. Dev Cell, 4:791–797.
58.
BrembeckFH, Schwarz-RomondT, BakkersJ, WilhelmS, HammerschmidtM and BirchmeierW. (2004). Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev, 18:2225–2230.
59.
MaH, NguyenC, LeeKS and KahnM. (2005). Differential roles for the coactivators CBP and P300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene, 24:3619–3631.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
